OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
May 01, 2023
FDA is encouraging sponsors to conduct studies and file applications for full approval of products authorized by Emergency Use Authorizations.
April 01, 2023
FDA has spurred investment to create and develop 600 therapies.
March 01, 2023
Advances in vaccine development are creating partnerships and stimulating clinical trials to develop new mRNA applications.
February 01, 2023
A Congressional probe of FDA’s approval of Alzheimer’s treatment targets the agency’s interactions with drug manufacturers.
January 01, 2023
Politics and drug shortages will continue to impact FDA and drug manufacturers in 2023.
December 01, 2022
Health crises, political tension, and budget concerns were major challenges.
November 01, 2022
FDA keeps its user fees but fails to gain important reforms.
October 01, 2022
FDA backs joint reviews, common research policies, and modern production methods around the world.
September 09, 2022
FDA is in jeopardy of losing its fees for assessing and approving new drugs and medical products.
August 01, 2022
FDA and the USPTO hope to promote competition by challenging strategies designed to block timely approval of generics and biosimilars.